Early versus deferred treatment for early stage multiple myeloma

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2003, Pages

  He, Yulong ^a   Wheatley, Keith ^b   Glasmacher, Axel ^c   Ross, Hamish ^d   Djulbegovic, Benjamin ^e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF BONN   (Germany)

^d NORTHAMPTON GENERAL HOSPITAL NHS TRUST   (United Kingdom)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ACUTE LEUKEMIA; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; DRUG EFFICACY; EARLY INTERVENTION; HUMAN; INTERVENTION STUDY; MORTALITY RATE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION; SYSTEMATIC REVIEW; THERAPY DELAY; TIME TO TREATMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; META ANALYSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

DISEASE PROGRESSION; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0037270651     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004023     Document Type: Review

References (28)

1. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. European Journal of Haematology 1993;50(2):95-102.
2. Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Alberio F, et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. British Journal of Cancer 1994;70(6):1203-10.
3. Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. British Journal of Cancer 2000;82(7):1254-60.
4. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. The New England Journal of Medicine 1994;330(7):484-9.
5. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001;134(8):663-94.
6. Anderson KC, Noga SJ, Bensinger Wea. NCCN practice guidelines for multiple myeloma. Oncology 1998;12:317-51.
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine 1996;335(2):91-7.
8. Castro AA, Clark AO, Atallah AN. Optimal search strategy for clinical trials in the Latin Anerican and Caribbean Health Science Literature Database (LILIACS). Revista paulista de medicina 1997;115:1423-1426.
9. Clarke M, Oxman AD. Cochrane Reviewer's Handbook 4.1 [update July 2000]. Oxford: The Cochrane Collaboration; Review Manager (Revman) 4.1. 1999.
10. Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, Kyle RA, Prager D, Rafla S, Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. Journal of Clinical Oncology 1986;4(9):1331-9.
11. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. Bmj 1994;309(6964):1286-91.
12. Djulbegovic B, Adams JR, Lyman GH, 23.Djulbegovic B, Adams JR, Lyman GH, et al. Evaluation and appraisal of randomized controlled trials in myeloma. Ann Oncology 2001;12:1611-1617.
13. Djulbegovic B, Clark O, Hozo I. Database for health outcomes and quality of randomized trials in multiple myeloma. Proceeding of American Society of Clinical Oncology 2002;21:251a.
14. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842-54.
15. Egger M, Smith DS, Altman D. Systematic reviews in health care. London: BMJ Books 2001;2nd ed.:87-108.
16. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood 1979;54(1):13-22.
17. Hussein M. Multiple myeloma: an overview of diagnosis and management. Cleveland Clinic Journal of Medicine 1994;61(4):285-98.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
19. Jadad A. Randomized Controlled Trials. London: BMJ Books. 1998.
20. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. Bmj 2001;323(7303):42-6.
21. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA: a Cancer Journal for Clinicians 1998;48(1):6-29.
22. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. Journal of Clinical Oncology 1998;16(12):3832-42.
23. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
24. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93; discussion 661-6.
25. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31(1):150-3.
26. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, Dixon DO. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology 1983;1(8):453-61.
27. Shakespeare TP, Gebski VJ, Veness MJ, Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet 2001;357(9265):1349-53.
28. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. Journal of Clinical Epidemiology 1998;51(12):1235-41.